BRAF and colorectal cancer: In addition, none of the previous studies [19], [20], [21], [22], [23], [24], [25] has comprehensively examined potential confounding effect of key molecular biomarkers in colorectal cancer, including the CpG island methylator phenotype (CIMP), and KRAS, BRAF and PIK3CA mutations.